Blinatumomab versus chemotherapy for advanced acute lymphoblastic leukemia H Kantarjian, A Stein, N Gökbuget, AK Fielding, AC Schuh, JM Ribera, ... New England Journal of Medicine 376 (9), 836-847, 2017 | 1911 | 2017 |
Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study MS Topp, N Gökbuget, AS Stein, G Zugmaier, S O'Brien, RC Bargou, ... The Lancet Oncology 16 (1), 57-66, 2015 | 1326 | 2015 |
Definition of relapse risk and role of nonanthracycline drugs for consolidation in patients with acute promyelocytic leukemia: a joint study of the PETHEMA and GIMEMA … MA Sanz, FL Coco, G Martın, G Avvisati, C Rayón, T Barbui, ... Blood, The Journal of the American Society of Hematology 96 (4), 1247-1253, 2000 | 830 | 2000 |
Bortezomib, melphalan, and prednisone versus bortezomib, thalidomide, and prednisone as induction therapy followed by maintenance treatment with bortezomib and thalidomide … MV Mateos, A Oriol, J Martínez-López, N Gutiérrez, AI Teruel, R de Paz, ... The lancet oncology 11 (10), 934-941, 2010 | 596 | 2010 |
A Modified AIDA Protocol With Anthracycline-Based Consolidation Results in High Antileukemic Efficacy and Reduced Toxicity in Newly Diagnosed PML/RAR-Positive Acute … MA Sanz, G Martı́n, C Rayón, J Esteve, M González, J Dı́az-Mediavilla, ... Blood, The Journal of the American Society of Hematology 94 (9), 3015-3021, 1999 | 542 | 1999 |
Mantle cell lymphoma: presenting features, response to therapy, and prognostic factors F Bosch, A López‐Guillermo, E Campo, JM Ribera, E Conde, MA Piris, ... Cancer: Interdisciplinary International Journal of the American Cancer …, 1998 | 472 | 1998 |
Standardized MRD quantification in European ALL trials: proceedings of the Second International Symposium on MRD assessment in Kiel, Germany, 18–20 September 2008 M Brüggemann, A Schrauder, T Raff, H Pfeifer, M Dworzak, OG Ottmann, ... Leukemia 24 (3), 521-535, 2010 | 452 | 2010 |
High-dose therapy intensification compared with continued standard chemotherapy in multiple myeloma patients responding to the initial chemotherapy: long-term results from a … J Bladé, L Rosiñol, A Sureda, JM Ribera, J Díaz-Mediavilla, ... Blood 106 (12), 3755-3759, 2005 | 411 | 2005 |
Risk-adapted treatment of acute promyelocytic leukemia based on all-trans retinoic acid and anthracycline with addition of cytarabine in consolidation therapy for … MA Sanz, P Montesinos, C Rayón, A Holowiecka, J De La Serna, ... Blood, The Journal of the American Society of Hematology 115 (25), 5137-5146, 2010 | 380 | 2010 |
Acute lymphoblastic leukaemia in adult patients: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up D Hoelzer, R Bassan, H Dombret, A Fielding, JM Ribera, C Buske Annals of Oncology 27, v69-v82, 2016 | 356 | 2016 |
Influence of pre-and post-transplantation responses on outcome of patients with multiple myeloma: sequential improvement of response and achievement of complete response are … JJ Lahuerta, MV Mateos, J Martínez-López, L Rosinol, A Sureda, ... Journal of Clinical Oncology 26 (35), 5775-5782, 2008 | 355 | 2008 |
Peripheral T-cell lymphomas: initial features, natural history, and prognostic factors in a series of 174 patients diagnosed according to the REAL Classification A Lopez-Guillermo, J Cid, A Salar, A Lopez, C Montalban, JM Castrillo, ... Annals of Oncology 9 (8), 849-855, 1998 | 347 | 1998 |
Outcome after relapse of acute lymphoblastic leukemia in adult patients included in four consecutive risk-adapted trials by the PETHEMA Study Group A Oriol, S Vives, JM Hernández-Rivas, M Tormo, I Heras, C Rivas, ... Haematologica 95 (4), 589, 2010 | 333 | 2010 |
Favorable outcome of patients with acute myeloid leukemia harboring a low-allelic burden FLT3-ITD mutation and concomitant NPM1 mutation: relevance to post … M Pratcorona, S Brunet, J Nomdedéu, JM Ribera, M Tormo, R Duarte, ... Blood, The Journal of the American Society of Hematology 121 (14), 2734-2738, 2013 | 319 | 2013 |
Comparison of the results of the treatment of adolescents and young adults with standard-risk acute lymphoblastic leukemia with the Programa Espanol de Tratamiento en … JM Ribera, A Oriol, MA Sanz, M Tormo, P Fernández-Abellán, E del Potro, ... Journal of Clinical Oncology 26 (11), 1843-1849, 2008 | 319 | 2008 |
Treatment of high-risk Philadelphia chromosome–negative acute lymphoblastic leukemia in adolescents and adults according to early cytologic response and minimal residual … JM Ribera, A Oriol, M Morgades, P Montesinos, J Sarra, ... Journal of Clinical Oncology 32 (15), 1595-1604, 2014 | 299 | 2014 |
Identification of novel cytogenetic markers with prognostic significance in a series of 968 patients with primary myelodysplastic syndromes F Sole, E Luno, C Sanzo, B Espinet, GF Sanz, J Cervera, MJ Calasanz, ... Haematologica 90 (9), 1168-1178, 2005 | 295 | 2005 |
Dasatinib and low-intensity chemotherapy in elderly patients with Philadelphia chromosome–positive ALL P Rousselot, MM Coudé, N Gokbuget, C Gambacorti Passerini, S Hayette, ... Blood, The Journal of the American Society of Hematology 128 (6), 774-782, 2016 | 291 | 2016 |
Prognostic value of immunophenotyping in multiple myeloma: a study by the PETHEMA/GEM cooperative study groups on patients uniformly treated with high-dose therapy G Mateo, MA Montalbán, MB Vidriales, JJ Lahuerta, MV Mateos, ... Journal of Clinical Oncology 26 (16), 2737-2744, 2008 | 289 | 2008 |
Sustained remissions of high-risk acute myeloid leukemia and myelodysplastic syndrome after reduced-intensity conditioning allogeneic hematopoietic transplantation: chronic … D Valcárcel, R Martino, D Caballero, J Martin, C Ferra, JB Nieto, ... Journal of Clinical Oncology 26 (4), 577-584, 2008 | 277 | 2008 |